NEW YORK, Jan. 25, 2024 /PRNewswire/ — The Textile Testing Equipment Market is projected for substantial growth, with a Compound Annual Growth Rate (CAGR) of 4.45%, according to a report by Technavio. The market is forecasted to witness an increase of USD 317.4 million between 2023 and 2028, driven by factors such as the rising demand… Continue reading Textile Testing Equipment Market is projected to grow at a CAGR of 4.45% between 2023 and 2028; Industry Trends, Driving Forces, Challenges and Market Forecast | Technavio
Category: Newswire
FS LUXEMBOURG S.À R.L. ANNOUNCES CASH TENDER OFFER AND CONSENT SOLICITATION
SÃO PAULO, Jan. 25, 2024 /PRNewswire/ — FS Luxembourg S.à r.l. (the “Issuer”), a wholly-owned finance subsidiary of FS Indústria de Biocombustíveis Ltda. (“FS Ltda.”), announces that Morgan Stanley & Co. LLC (the “Offeror”), with the consent of the Issuer, has commenced a cash tender offer (the “Tender Offer”) for any and all of the outstanding US$446,317,000 aggregate… Continue reading FS LUXEMBOURG S.À R.L. ANNOUNCES CASH TENDER OFFER AND CONSENT SOLICITATION
Vantage Awarded “Best-in-Class Social Copy Trading” Yet Again
PORT VILA, Vanuatu, Jan. 25, 2024 /PRNewswire/ — Global multi-asset broker, Vantage (or Vantage Markets), is honoured to receive the prestigious “Best-in-Class Social Copy Trading” award from Forexbrokers.com for the second consecutive year. This accolade reaffirms Vantage’s unwavering commitment to excellence in the copy trading space. Continue Reading Vantage Awarded “Best-in-Class Social Copy Trading” Yet Again… Continue reading Vantage Awarded “Best-in-Class Social Copy Trading” Yet Again
IMA Signs MoU with Al Akhawayn University to Enhance Management Accounting Education
DUBAI, UAE, Jan. 25, 2024 /PRNewswire/ — IMA®️ (Institute of Management Accountants) and Al Akhawayn University have signed a Memorandum of Understanding (MoU), marking a significant step in enriching the academic and professional landscape for students in Morocco and the broader Middle East region. Continue Reading Al Akhawayn University Under this agreement, Al Akhawayn University… Continue reading IMA Signs MoU with Al Akhawayn University to Enhance Management Accounting Education
MBLY INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Mobileye Global Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!
NEW YORK, Jan. 25, 2024 /PRNewswire/ — Attorney Advertising — Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Mobileye Global Inc. (“Mobileye” or “the Company”) (NASDAQ: MBLY) and certain of its officers. Class Definition: This lawsuit seeks to recover damages against Defendants… Continue reading MBLY INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Mobileye Global Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!
Jacobs Awarded $132 Million UK Ministry of Defence Research and Technology Contract
Supports safe operation of Royal Navy submarines DALLAS, Jan. 25, 2024 /PRNewswire/ — Jacobs (NYSE:J) was selected to supply research and technology services to the United Kingdom’s naval nuclear propulsion program. The $132 million (£108 million) contract, which runs until 2032, covers essential through-life technical support for the reactors which power the Royal Navy’s submarines,… Continue reading Jacobs Awarded $132 Million UK Ministry of Defence Research and Technology Contract
De vastes capacités de R&D：ICP DAS – BMP présentera une large gamme de TPU de qualité médicale au MD&M 2024, aux États-Unis
HSINCHU, 25 janvier 2024 /PRNewswire/ — ICP DAS – BMP, le premier fournisseur asiatique de polyuréthane thermoplastique (TPU) de qualité médicale, fera ses débuts aux États-Unis à l’occasion du salon MD&M West. Pour lancer cette année 2024, l’entreprise présente une gamme complète de TPU de qualité médicale aux experts les plus éminents et à un… Continue reading De vastes capacités de R&D：ICP DAS – BMP présentera une large gamme de TPU de qualité médicale au MD&M 2024, aux États-Unis
FTFT INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Future FinTech Group Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!
NEW YORK, Jan. 25, 2024 /PRNewswire/ — Attorney Advertising — Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Future FinTech Group Inc. (“Future FinTech” or “the Company”) (NASDAQ: FTFT) and certain of its officers. Class Definition: This lawsuit seeks to recover damages… Continue reading FTFT INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Future FinTech Group Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!
Databarracks achieves ISO 22301 certification for Business Continuity Management Systems
Technology and Business Resilience specialist Databarracks has successfully achieved ISO 22301 certification. LONDON, Jan. 25, 2024 /PRNewswire/ — Databarracks provides award-winning IT resilience and continuity. With ISO 22301, the company has implemented the globally recognised standard to further improve its offering and service delivery. ISO 22301 is an international standard which defines the requirements and… Continue reading Databarracks achieves ISO 22301 certification for Business Continuity Management Systems
Asieris will Present For the First Time Interim Analysis Data of Oral APL-1202 in Combination with PD-1 Inhibitor Tislelizumab for Neoadjuvant Treatment of Muscle-Invasive Bladder Cancer at 2024 ASCO-GU
SHANGHAI, Jan. 25, 2024 /PRNewswire/ — Asieris Pharmaceuticals (Stock Code: 688176.SH), a global biopharmaceutical company specializing in discovering, developing, and commercializing innovative drugs for the treatment of genitourinary tumors and other related diseases, announced that the interim analysis data from the Phase II clinical trial of oral APL-1202 in combination with PD-1 inhibitor tislelizumab as neoadjuvant… Continue reading Asieris will Present For the First Time Interim Analysis Data of Oral APL-1202 in Combination with PD-1 Inhibitor Tislelizumab for Neoadjuvant Treatment of Muscle-Invasive Bladder Cancer at 2024 ASCO-GU